New approaches to the treatment of endometriosis

Т. Ф Татарчук, Н. Ф. Захаренко, Т. Н. Тутченко
In: Reproductive Endocrinology · 2013 · vol. 0(11) , pp. 36 · doi:10.18370/2309-4117.2013.11.36-42 · W2220129560
article OA: diamond CC0 ⤵ 5 in-corpus citations
🔓 Open OA copy View on OpenAlex View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-09 ⓘ

This study found that the non-hormonal drug L-arginine (Tivortin) impacts factors involved in endometriosis development and progression, showing promise for treatment and recurrence prevention in 64 women.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

The results of the study that involving 64 women with endometriosis have shown that the use in the treatment of L-arginine (the drug Tivortin) has a direct impact on the underlying factors that play role in the development and progression of endometriosis. It makes the use of non-hormonal drug promising in treatment of endometriosis andhas an important role in the prevention of its recurrence.

My notes (saved in your browser only)

Condition tags

endometriosis

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (20)

Cited by (5)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK